Literature DB >> 9708639

Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients.

A Pawarode1, N Voravud, V Sriuranpong, P Kullavanijaya, Y Z Patt.   

Abstract

Primary hepatocellular carcinoma (HCC) is a common malignancy with a dismal prognosis; new modalities of treatment as alternatives to surgery have been developed for unresectable patients. The authors obtain baseline data for the natural history of HCC so that the efficacy of new treatments may be evaluated. A retrospective study of 157 untreated patients with tissue-proven or serodiagnosed HCC was conducted. Clinical characteristics including laboratory investigation, treatment received, survival from the time of diagnosis, and prognostic factors were evaluated. There were 129 men and 28 women (ratio, 4.6:1). Median age was 50.9 years (range, 14.1-85.3 years). The most common symptoms and signs were weight loss (68.2%), abdominal fullness (62.5%), abdominal pain (51.6%), hepatomegaly (73.7%), ascites (45.2%), and jaundice (40.6%). Eighteen percent had extrahepatic metastases of which the lungs were the most common site. Seventy percent were hepatitis B virus related. Overall median survival was 8.7 weeks after the time of diagnosis. Survivals by stages were: TNM II, 16.6 weeks; TNM III, 7.3 weeks; TNM IVA, 9.7 weeks; TNM IVB, 7.6 weeks; Okuda II, 10.7 weeks; and Okuda III, 7.3 weeks. Multivariate analysis revealed serum total bilirubin and albumin as independent prognostic factors of survival. Common causes of death were upper gastrointestinal hemorrhage (34.1%), cancer-related causes (cachexia, HCC rupture, metastatic disease, 31.8%), and hepatic failure (25.0%). Patients with HCC were diagnosed at late stages of their disease and the advanced nature of the tumor precluded effective therapy. Earlier tumor detection at a time when patients are better candidates for treatment may be aided by an active surveillance program of high risk groups.

Entities:  

Mesh:

Year:  1998        PMID: 9708639     DOI: 10.1097/00000421-199808000-00014

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  50 in total

1.  Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jia Fan; Jian Zhou; Zhi-Quan Wu; Shuang-Jian Qiu; Xiao-Ying Wang; Ying-Hong Shi; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

2.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

3.  Controversies in imaging of hepatocellular carcinoma: multidetector CT (MDCT).

Authors:  Paul M Silverman; Janio Szklaruk
Journal:  Cancer Imaging       Date:  2005-12-10       Impact factor: 3.909

4.  A large Right atrial mass in a patient with hepatocellular carcinoma: Case report and literature review.

Authors:  Hanan B Albackr
Journal:  J Saudi Heart Assoc       Date:  2014-02-20

5.  Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.

Authors:  Takashi Niizeki; Shuji Sumie; Takuji Torimura; Junichi Kurogi; Ryoko Kuromatsu; Hideki Iwamoto; Hajime Aino; Masahito Nakano; Atsushi Kawaguchi; Tatsuyuki Kakuma; Michio Sata
Journal:  J Gastroenterol       Date:  2012-03-01       Impact factor: 7.527

Review 6.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

7.  Hepatocellular Carcinoma With Intra-atrial Extension Responding to Transarterial Chemoembolization via the Right Hepatic and Right Inferior Phrenic Arteries.

Authors:  Maen W H Kamal; Maham Farshidpour; Andrew W Long; Saleem Farooqui; Steven C Cunningham
Journal:  Gastrointest Cancer Res       Date:  2014-05

Review 8.  Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience.

Authors:  Masashi Mizumoto; Yoshiko Oshiro; Toshiyuki Okumura; Nobuyoshi Fukumitsu; Haruko Numajiri; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Int J Part Ther       Date:  2016-03-24

9.  Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis.

Authors:  Shinji Sugahara; Hidetsugu Nakayama; Kuniaki Fukuda; Masashi Mizumoto; Mari Tokita; Masato Abei; Junichi Shoda; Yasushi Matsuzaki; Eriko Thono; Koji Tsuboi; Koichi Tokuuye
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

Review 10.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.